Advancements and Milestones in Neuropsychiatry Drug Development by Cybin Inc.
Update: 2025-09-24
Description
Cybin Inc. provided updates on its drug discovery platforms, highlighting key milestones such as upcoming Phase 2 and Phase 3 program data releases for anxiety and depression disorders, along with a strategic manufacturing partnership. The Company's intellectual property portfolio is secured until 2041, with promising response rates and FDA Breakthrough Therapy Designation for its CYB003 program.
Comments
In Channel
Download from Google Play
Download from App Store
United States00:00
00:00
x
